Trial NCT03059511

View at ClinicalTrials.gov 
Org. Study IDs: PK_Nalbuphin_iv_intranasal

Last trial update was posted on 2021-12-14

MeSH Interventions

Nalbuphine

MeSH Conditions


Other Conditions

Pharmacokinetic

Stopping Reasons

We conclude that the doses we administered were safe, but too low. We plan to continue the study with higher doses (0.1 mg/kg iv and 0.2 mg/kg intranasal).

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID